Key result
The use of BNP or NT-proBNP in dyspneic patients early following admission to the emergency department reduces the time to discharge and total treatment cost.
Why the study?
Does the early use of BNP or NT-proBNP improve the diagnosis of congestive heart failure and reduce time to discharge and costs in patients presenting to the emergency department with acute dyspnea?
Does the early use of BNP or NT-proBNP improve the diagnosis of congestive heart failure and reduce time to discharge and costs in patients presenting to the emergency department with acute dyspnea?
Early measurement of BNP or NT-proBNP in the emergency department is beneficial for the accurate diagnosis of heart failure and reduces treatment costs and time to discharge.
May shorten ED stays and cut costs with early BNP/NT-proBNP; leaves open confirmation by RCTs before practice change.
Congestive heart failure (CHF) is the main cause of acute dyspnea in patients presenting to an emergency department (ED) and is associated with high morbidity and mortality. B-type natriuretic peptide (BNP) is a polypeptide, released by ventricular myocytes in direct proportion to wall tension, which lowers renin-angiotensin-aldosterone activation. For the diagnosis of CHF, both BNP and the biologically inactive NT-proBNP have similar accuracy. Threshold values are higher in an elderly population, and in patients with renal dysfunction. They might also have a prognostic value. Studies have demonstrated that the use of BNP or NT-proBNP in dyspneic patients early following admission to the ED, reduced the time to discharge and total treatment cost. BNP and NT-proBNP should be available in every ED 24 h a day, because the literature strongly suggests the beneficial impact of an early appropriate diagnosis and treatment in dyspneic patients. The purpose of this review is to indicate recent developments in biomarkers of heart failure and to evaluate their impact on clinical use in the emergency setting.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2008) conducted a review in Acute dyspnea and congestive heart failure. B-type natriuretic peptide (BNP) and NT-proBNP was evaluated. The use of BNP or NT-proBNP in dyspneic patients early following admission to the emergency department reduces the time to discharge and total treatment cost.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: